Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
|Articles|December 2, 2018
- Pharmaceutical Technology-12-02-2018
- Volume 42
- Issue 12
150-Gallon Double Planetary Mixers
Charles Ross & Son Company recently developed two specialty customized 150-gallon double planetary mixers (Model DPM-150) with patented high viscosity blades.
Advertisement
Charles Ross & Son Company recently developed two specialty customized 150-gallon double planetary mixers (Model DPM-150) with patented high viscosity blades. Features include interchangeable jacketed vessels, electrohydraulic lift, recipe controls with data logger, and an all stainless-steel sanitary design. The mixers consist of two identical blades that move in a planetary motion, rotating on their own axes as they orbit a common axis. In 36 revolutions around the vessel, the two blades pass through every point in the product zone, physically contacting the entire batch. When mixing high viscosity products upwards of two million centipoise, the blades impart a kneading action to the batch, smoothing out its consistency and breaking up any agglomerates.
Articles in this issue
almost 8 years ago
Sterile, Integrated Hood and Mask for Larger Heads and Hairstylesalmost 8 years ago
Scaling Up and Launching Solid-Dosage Drugsalmost 8 years ago
Developing and Manufacturing Transdermal Patchesalmost 8 years ago
Spray Film Provides Alternative to Patchesalmost 8 years ago
Improving Production: How IT, OT, and Quality Can Collaboratealmost 8 years ago
Manufacturing Considerations for Transdermal Delivery Systemsalmost 8 years ago
Investigation Timeliness vs. Thoroughness: Finding the Right Balancealmost 8 years ago
Microbial Identification Strategies for Bioburden Controlalmost 8 years ago
Fighting Bacterial Resistance with Biologicsalmost 8 years ago
The Key Word: QualityAdvertisement
Related to this article
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Advertisement
Advertisement